A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Pfizer
Centre Oscar Lambret
Vejle Hospital
Memorial Sloan Kettering Cancer Center
University Hospital, Rouen
Kyungpook National University Hospital
Kyungpook National University Hospital
University Hospital, Rouen
Roswell Park Cancer Institute
Vaccinogen Inc
The Royal Wolverhampton Hospitals NHS Trust
GlaxoSmithKline
National Cancer Institute (NCI)
Massachusetts General Hospital
Qilu Pharmaceutical Co., Ltd.
Norwegian Department of Health and Social Affairs
UNICANCER
Centre Hospitalier Universitaire, Amiens
Sahlgrenska University Hospital
IFOM ETS - The AIRC Institute of Molecular Oncology
First Affiliated Hospital of Guangxi Medical University
Pfizer
Sun Yat-sen University
Georgetown University
Swiss Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris
University of Leeds
Nakafarma S.L.
Hutchmed
Centre Hospitalier Universitaire Dijon
Charite University, Berlin, Germany
Sun Yat-sen University
Peter MacCallum Cancer Centre, Australia
the BELOOSTROV Clinic of High Technologies
Mirati Therapeutics Inc.
Jiangsu Famous Medical Technology Co., Ltd.
Alliance for Clinical Trials in Oncology
Seoul National University Hospital
Zhejiang Cancer Hospital
Zhejiang Cancer Hospital
Medical University of Vienna
Federation Francophone de Cancerologie Digestive
Thomas Jefferson University
Russian Society of Colorectal Surgeons
University Hospital, Antwerp
Leiden University Medical Center